EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT

Andrea Carolina Quiroga-Centeno iD, Konstantina Atanasova iD, Matthias Philip Ebert iD, Anne Kerstin Thomann iD, Wolfgang Reindl iD

Seminars in Immunopathology · 2025-12 · 47 (1)

DOI: 10.1007/s00281-025-01066-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Immunopathology, online erschienen am 25.11.2025. Verfasst von Andrea Carolina Quiroga-Centeno und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. caroline_aqc@hotmail.com. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Fecal Microbiota Transplantation, Gastrointestinal Microbiome. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Fakultät Mannheim der Universität Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) is a multifactorial and heterogeneous disorder that remains challenging to manage. Growing evidence implicates the gut microbiome as a key player in IBD pathogenesis, with many patients displaying intestinal dysbiosis that can drive aberrant immune responses. Traditional microbiome-targeted interventions, such as dietary modifications, probiotics, and fecal microbiota transplantation (FMT), have yielded mixed and often temporary benefits in IBD. This shortcoming of broad-spectrum approaches underscores the need for more precise, personalized strategies that account for each patient’s unique microbiota and disease phenotype. Recent advances in omics and bioengineering have catalyzed the development of emerging microbiome-directed therapies that move beyond these broad approaches. This narrative review highlights emerging microbiome-directed therapies that aim to restore gut homeostasis and mitigate inflammation in IBD. We critically evaluate the rationale and therapeutic potential of rationally designed bacterial consortia and genetically engineered bacteria, which represent next-generation probiotics tailored to complement deficient microbial functions or deliver anti-inflammatory agents in situ. We also expand the discussion to underexplored microbiome constituents – archaea, protists, bacteriophages, and fungi – highlighting their roles in IBD and potential as therapeutic targets. Finally, we discuss the key advances and ongoing challenges of these innovative approaches, from ecological stability and engraftment to safety and regulatory considerations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesFecal Microbiota TransplantationGastrointestinal MicrobiomeHumansProbioticsAnimalsDysbiosis

Stichwörter der Autor:innen

DysbiosisGastrointestinal microbiomeInflammatory bowel diseasePrecision medicineTherapy

Autor:innen und Institutionen

  • Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. caroline_aqc@hotmail.com.
  • Department of Surgery, Universidad Industrial de Santander, Bucaramanga, Colombia. caroline_aqc@hotmail.com.
  • Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • DKFZ-Hector Cancer Institute at the University Medical Center, Mannheim, Germany.
  • Molecular Medicine Partnership Unit, European Molecular Biology Laboratory, Heidelberg, Germany.

ORCID-Profile: Andrea Carolina Quiroga-Centeno, Konstantina Atanasova, Matthias Philip Ebert, Anne Kerstin Thomann, Wolfgang Reindl

Förderung

  • Medizinische Fakultät Mannheim der Universität Heidelberg

Zitieren

APA

Quiroga-Centeno, A. C., Atanasova, K., Ebert, M. P., Thomann, A. K., & Reindl, W. (2025). Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT. Seminars in Immunopathology, 47(1). https://doi.org/10.1007/s00281-025-01066-5

Vancouver

Quiroga-Centeno AC, Atanasova K, Ebert MP, Thomann AK, Reindl W. Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT. Seminars in Immunopathology. 2025;47(1). doi:10.1007/s00281-025-01066-5

BibTeX
@article{QuirogaCenteno2025,
  author = {Quiroga-Centeno, Andrea Carolina and Atanasova, Konstantina and Ebert, Matthias Philip and Thomann, Anne Kerstin and Reindl, Wolfgang},
  title = {Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT},
  journal = {Seminars in Immunopathology},
  year = {2025},
  volume = {47},
  number = {1},
  doi = {10.1007/s00281-025-01066-5}
}
Kostenlos starten →